| Literature DB >> 28562585 |
Ali Jazayeri1, Mathieu Rappas1, Alastair J H Brown1, James Kean1, James C Errey1, Nathan J Robertson1, Cédric Fiez-Vandal1, Stephen P Andrews1, Miles Congreve1, Andrea Bortolato1, Jonathan S Mason1, Asma H Baig1, Iryna Teobald1, Andrew S Doré1, Malcolm Weir1, Robert M Cooke1, Fiona H Marshall1.
Abstract
Glucagon-like peptide 1 (GLP-1) regulates glucose homeostasis through the control of insulin release from the pancreas. GLP-1 peptide agonists are efficacious drugs for the treatment of diabetes. To gain insight into the molecular mechanism of action of GLP-1 peptides, here we report the crystal structure of the full-length GLP-1 receptor bound to a truncated peptide agonist. The peptide agonist retains an α-helical conformation as it sits deep within the receptor-binding pocket. The arrangement of the transmembrane helices reveals hallmarks of an active conformation similar to that observed in class A receptors. Guided by this structural information, we design peptide agonists with potent in vivo activity in a mouse model of diabetes.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28562585 DOI: 10.1038/nature22800
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962